Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly misrepresenting the company's development progress and overstating achievements in prostate cancer therapeutics during the Class Period from February 21, 2025, to August 28, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities during the specified Class Period [1]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations - The complaint alleges that the defendants misrepresented the company's business operations, including the reliability of its supply chain and partners, leading to materially false or misleading statements [3]. - As a result of these misrepresentations, investors experienced significant losses when the truth about the company's business was revealed [3]. Group 3: Company Background - Telix Pharmaceuticals is based in Melbourne, Australia, and focuses on radiopharmaceutical therapies and diagnostics for oncology [2].

U.S. stocks were higher, with the Dow Jones index gaining more than 250 points on Friday.Shares of Carnival PLC (NYSE:CUK) rose sharply during Thursday's session after the company announced better-than-expected fourth-quarter adjusted EPS results and issuedFY26 adjusted EPS guidance above estimates.Carnival shares jumped 16.3% to $30.61 on Friday.Here are some other big stocks recording gains in today’s session.NovaBay Pharmaceuticals Inc (NYSE:NBY) shares jumped 45.1% to $4.28.Intuitive Machines Inc (NASDA ...

Core Insights - Pfizer's stock has declined approximately 3% this week following the announcement of its financial guidance for 2026, which did not meet investor expectations [1] Financial Guidance - Pfizer anticipates total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting modest growth from the revised 2025 revenue expectation of around $62 billion, primarily due to lower revenues from COVID products and the impending patent cliff [2] - The company expects adjusted earnings per share in the range of $2.80 to $3.00 for 2026, a decline from the 2025 expected range of $3.00 to $3.15, influenced by the dilutive impact of recent deals and lower COVID revenues [3] Oncology Segment - Pfizer holds a strong position in oncology, with oncology sales accounting for approximately 28% of total revenues, which have increased by 7% in the first nine months of 2025 [4][5] - The company is advancing its oncology pipeline and expects to have eight or more blockbuster oncology medicines by 2030 [5] Product Development and Acquisitions - Pfizer is focusing on expanding its product labels and has in-licensed rights for new oncology treatments, including a dual PD-1 and VEGF inhibitor [6][7] - The company has reduced its dependence on COVID-related revenues, with non-COVID operational revenues improving due to key products and new acquisitions, which are expected to deliver double-digit growth in 2026 [8][9] Challenges and Headwinds - Pfizer is facing a significant revenue impact from the loss of exclusivity for several key products between 2026 and 2030, which is projected to reduce sales by approximately $1.5 billion in 2026 [15] - The company is also experiencing lower sales of COVID products due to decreased vaccination and infection rates, with expected COVID revenues around $5 billion in 2026, down from $6.5 billion in 2025 [12][14] Stock Performance and Valuation - Pfizer's stock has underperformed compared to the industry and the S&P 500, losing 4.9% year-to-date [17] - The stock is currently trading at a price/earnings ratio of 8.04, significantly lower than the industry average of 17.11 and its five-year mean of 10.41, indicating potential attractiveness for investors [20] Future Outlook - Despite current challenges, Pfizer's key drugs and new product launches are expected to help offset losses from patent expirations, with anticipated cost savings of $7.7 billion by the end of 2027 [26] - The company is viewed as a hold in investment portfolios as it rebuilds its pipeline in oncology and obesity, which could drive growth from 2029 onwards [27]

Core Viewpoint - Merck is expected to face significant challenges impacting its long-term growth outlook, primarily due to the impending loss of exclusivity for its leading drug, Keytruda, in 2028, despite recent sales growth [1][11]. Group 1: Keytruda and Revenue Impact - Keytruda, a PD-L1 inhibitor, generated sales of $23.3 billion in the first nine months of 2025, marking an 8% year-over-year increase and accounting for over 50% of Merck's pharmaceutical sales [1][2]. - The intravenous formulation of Keytruda will lose patent exclusivity in 2028, prompting Merck to develop a subcutaneous formulation, Keytruda Qlex, which has its own patents extending beyond 2028 [3]. - The anticipated loss of exclusivity for Keytruda is a major concern for Merck's revenue stability moving forward [11]. Group 2: Declining Sales of Gardasil - Gardasil, Merck's second-largest product, saw sales of $4.20 billion in the first nine months of 2025, reflecting a 40% decline year over year, primarily due to weak demand in China and Japan [4][5]. - Management expects continued weakness in Gardasil sales in these markets as they head into 2026 [5]. Group 3: Regulatory and Competitive Challenges - The redesign of Medicare Part D under the Inflation Reduction Act, effective in 2025, poses additional challenges, with drugs like Januvia and Janumet facing government price setting starting in 2026 and 2027, respectively [6][7]. - Keytruda is also expected to be subject to government price setting in 2027, which could further impact U.S. sales post-2029 [7]. Group 4: Future Growth Prospects - Merck is focusing on new products like the 21-valent pneumococcal conjugate vaccine, Capvaxive, and the pulmonary arterial hypertension drug, Winrevair, to drive revenue growth after Keytruda's exclusivity ends [8]. - The Animal Health business is contributing positively to Merck's growth, and the company aims to achieve $3 billion in annual cost savings by the end of 2027 through optimization initiatives [9]. Group 5: Market Performance and Valuation - Merck's shares have increased by 27.5% over the past six months, outperforming the industry average of 19% [14]. - The company's price/earnings ratio stands at 11.56, which is lower than the industry average of 17.11 and its five-year mean of 12.49, indicating attractive valuation [15]. - The Zacks Consensus Estimate for 2025 earnings per share has risen from $8.92 to $8.98, while the estimate for 2026 has decreased from $9.44 to $8.37 [17].

PresentationThank you for standing by. My name is Jayel, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin business update. [Operator Instructions] I would now like to turn the conference over to Traci McCarthy, Head of Investor Relations. You may begin. Perhaps, your line is on mute, Traci.Traci McCartyGroup Vice President Thank you, Jayel, and good morning, everyone. Thank you for joining us to discuss BioMarin's acquisition of Amicus Therapeutics ...

Core Insights - Moderna (MRNA) has received up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support a pivotal phase III study of its mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018 [1][8] Group 1: Study Details - The phase III study will be the first of its kind for an mRNA-based pandemic influenza vaccine and is set to begin in early 2026 [2][8] - The study will assess the safety and immunogenicity of mRNA-1018 in the U.S. and the U.K., building on positive phase I/II data [3][8] - Potential licensure may also depend on data from a phase III study of Moderna's seasonal influenza vaccine, mRNA-1010 [3] Group 2: Global Impact and Accessibility - If approved, Moderna plans to allocate 20% of its H5 vaccine production for low and middle-income countries at affordable prices [4][8] - The mRNA-1018 vaccine would enhance the global H5 vaccine portfolio and support CEPI's goal of developing effective vaccines within 100 days of identifying a new pandemic threat [9] Group 3: Broader Development Activities - The project is part of a larger collaboration between CEPI and Moderna aimed at rapidly developing vaccines for epidemic and pandemic threats using mRNA technology [6] - Moderna is currently developing over 40 mRNA-based investigational candidates across various clinical stages, targeting multiple indications including cancer [9][10] Group 4: Market Performance - Over the past six months, Moderna's shares have increased by 19.5%, while the industry has risen by 22.4% [5] - Following the end of the COVID-19 pandemic, sales of Moderna's COVID-19 vaccines have significantly declined, making the successful development of other vaccine candidates crucial for the company [11]

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. ...

US President Donald Trump is expected to announce new agreements on Friday (December 19) aimed at lowering prescription drug prices, the White House said. The announcement is scheduled for 1 p.m. ET at the White House.AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among the major pharmaceutical companies expected to participate, Reuters reporting citing sources familiar with the matter.Swiss drugmakers Novartis and Roche are also reportedly part of the deals, according to Bloomberg News.Backgr ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) --  Faruqi & Faruqi, LLP, a ...

同日，苗药龙头股贵州百灵发布公告，贵州百灵及相关当事人收到贵州证监局出具的《行政处 罚事先告知书》，因贵州百灵披露的2019年至2021年及2023年年报存在虚假记载，深圳证券 交易所将对贵州百灵股票实施其他风险警示。 贵州百灵股票 自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。 自2025年 12月23日开市起，贵州百灵股票简称由"贵州百灵" 变更为"ST百灵" ，股票代码不变，仍 为"002424"，股票交易日涨跌幅限制由10%变为5%。 截至12月19日，贵州百灵股价报5.63元，总市值79亿元，今年以来累计上涨超46%。 贵州百灵财务造假遭重罚 对此你有什么想说的？ 欢迎评论区聊聊~ （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 出品丨21财经客户端 21世纪经济报道 理想汽车组织架构调整，涉近千人，原零部件负责人离职 热搜第一，牛股瞬间闪崩12个点，网友：炒股用曲面屏太难受 SFC 21君荐读 记者丨曾静娇 编辑丨刘雪莹 12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵企业集团制药股份有限 公司(以下简称"贵州百灵")涉嫌定期 ...